152 related articles for article (PubMed ID: 35235189)
21. A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
Claudiani S; Janssen JJWM; Byrne J; Smith G; Blijlevens N; Raghavan M; Smith M; Clark RE; Mclain-Smith S; Carter AM; Milojkovic D; Apperley JF
Eur J Haematol; 2022 Jul; 109(1):90-99. PubMed ID: 35403752
[TBL] [Abstract][Full Text] [Related]
22. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
23. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S; Keller-v Amsberg G; Schafhausen P; Koschmieder S; Brümmendorf TH
Recent Results Cancer Res; 2014; 201():81-97. PubMed ID: 24756786
[TBL] [Abstract][Full Text] [Related]
24. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Hill BG; Kota VK; Khoury HJ
Expert Rev Anticancer Ther; 2014 Jul; 14(7):765-70. PubMed ID: 24875651
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
26. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.
Isfort S; Crysandt M; Gezer D; Koschmieder S; Brümmendorf TH; Wolf D
Recent Results Cancer Res; 2018; 212():87-108. PubMed ID: 30069626
[TBL] [Abstract][Full Text] [Related]
27. Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.
Levy M; Xie L; Wang Y; Neumann F; Srivastava S; Naranjo D; Xu J; Zhang Q; Dalal M
Cancer Treat Res Commun; 2021; 28():100424. PubMed ID: 34198039
[TBL] [Abstract][Full Text] [Related]
28. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study.
Rosti G; Brümmendorf TH; Gjertsen BT; Giraldo-Castellano P; Castagnetti F; Gambacorti-Passerini C; Ernst T; Zhao H; Kuttschreuter L; Purcell S; Giles FJ; Hochhaus A
Leukemia; 2024 Jan; 38(1):126-135. PubMed ID: 38007586
[TBL] [Abstract][Full Text] [Related]
29. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
Brivio E; Pennesi E; Willemse ME; Huitema ADR; Jiang Y; van Tinteren HDR; van der Velden VHJ; Beverloo BH; den Boer ML; Rammeloo LAJ; Hudson C; Heerema N; Kowalski K; Zhao H; Kuttschreuter L; Bautista Sirvent FJ; Bukowinski A; Rizzari C; Pollard J; Murillo-Sanjuán L; Kutny M; Zarnegar-Lumley S; Redell M; Cooper S; Bertrand Y; Petit A; Krystal J; Metzler M; Lancaster D; Bourquin JP; Motwani J; van der Sluis IM; Locatelli F; Roth ME; Hijiya N; Zwaan CM
J Clin Oncol; 2024 Mar; 42(7):821-831. PubMed ID: 38033284
[TBL] [Abstract][Full Text] [Related]
30. The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Unkrig C; Enzmann H; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2014 Apr; 19(4):421-5. PubMed ID: 24668331
[TBL] [Abstract][Full Text] [Related]
31. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
32. Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia.
Garrett M; Knight B; Cortes JE; Deininger MW
Cancer Med; 2023 Sep; 12(17):17981-17992. PubMed ID: 37553873
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
34. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.
Cortes JE; Gambacorti-Passerini C; Kim DW; Kantarjian HM; Lipton JH; Lahoti A; Talpaz M; Matczak E; Barry E; Leip E; Brümmendorf TH; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):684-695.e6. PubMed ID: 28807791
[TBL] [Abstract][Full Text] [Related]
35. Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Levy MY; McGarry LJ; Huang H; Lustgarten S; Chiroli S; Iannazzo S
Curr Med Res Opin; 2019 Mar; 35(3):479-487. PubMed ID: 30086654
[TBL] [Abstract][Full Text] [Related]
36. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
[TBL] [Abstract][Full Text] [Related]
37. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL;
Ann Hematol; 2019 Feb; 98(2):321-330. PubMed ID: 30446802
[TBL] [Abstract][Full Text] [Related]
39. Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Caocci G; Mulas O; Abruzzese E; Iurlo A; Annunziata M; Orlandi EM; Galimberti S; Binotto G; Sgherza N; Luciano L; Martino B; Russo Rossi A; Bonifacio M; Fozza C; Trawinska MM; Cattaneo D; Elena C; Baratè C; De Gregorio F; Molica M; La Nasa G; Foà R; Breccia M
Ann Hematol; 2019 Aug; 98(8):1885-1890. PubMed ID: 31044260
[TBL] [Abstract][Full Text] [Related]
40. The role of bosutinib in the treatment of chronic myeloid leukemia.
Gambacorti-Passerini C; le Coutre P; Piazza R
Future Oncol; 2020 Jan; 16(2):4395-4408. PubMed ID: 31833784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
